EGF upregulates Na+/H+ exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness

Journal of Cellular Physiology

Volumn 214, Issue 3, 2008, Pages 810-819

  Chiang, Yihan ^a   Chou, Cheng Yang ^a   Hsu, Keng Fu ^a   Huang, Yu Fang ^a   Shen, Meng Ru ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; EPIDERMAL GROWTH FACTOR; EZRIN; PHOSPHATIDYLINOSITOL 3 KINASE; SODIUM PROTON EXCHANGE PROTEIN 1; CATION TRANSPORT PROTEIN; SLC9A1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL VOLUME; CONTROLLED STUDY; CYTOSKELETON; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LAMELLIPODIUM; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; CELL MOTION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN TRANSPORT; PSEUDOPODIUM; TREATMENT OUTCOME; TUMOR CELL LINE; UPREGULATION; UTERINE CERVIX TUMOR;

ADULT; AGED; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PSEUDOPODIA; SODIUM-HYDROGEN ANTIPORTER; TREATMENT OUTCOME; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 38449102040     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21277     Document Type: Article

References (39)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. 1987. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245.
2. Araújo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV. 2007. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer - a review of the literature. Oncologist 12:201-210.
3. Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M. 2006. Prospect for anti-HER2 receptor therapy in breast cancer. Anticancer Res 26:463-470.
4. + exchanger in metastasis. Nat Rev Cancer 5:786-795.
5. Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A, Casavola V, Zaccolo M, Reshkin SJ. 2005b. Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/ NHE1 signal module regulates invasion in breast cancer cell lines. Mol Biol Cell 16:3117-3127.
6. Chang LC, Wang JP. 2001. Signal transduction pathways for activation of extracellular signal-regulated kinase by arachidonic acid in rat neutrophils. J Leukoc Biol 69: 659-665.
7. Chen HC. 2005. Boyden chamber migration assay. Methods Mol Biol 294:15-22.
8. Chou CY, Shen MR, Wu SN. 1995. Volume-sensitive chloride channels associated with human cervical carcinogenesis. Cancer Res 55:6077-6083.
9. + exchanger N HE1. J Cell Biol 159:1087-1096.
10. + translocation. Mol Cell 6:1425-1436.
11. -3 exchanger isoforms in proximal and distal human airways. Am J Physiol 276:L971-978.
12. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M. 2006. Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13:3483-3492.
13. Karmazyn M. 2001. Role of sodium-hydrogen exchange in cardiac hypertrophy and heart failure: A novel and promising therapeutic target. Basic Res Cardiol 96:325-328.
14. + exchanger N HE1. J Cell Sci 113:3649-3662.
15. + exchanger. Can J Physiol Pharmacol 84:1081-1095.
16. + exchanger N HE1. FEBS Lett 521:205-210.
17. Mosesson Y, Yarden Y. 2004. Oncogenic growth factor receptors: Implications for signal transduction therapy. Semin Cancer Biol 14:262-270.
18. Ono M, Kuwano M. 2006. Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and response to Gefitinib and Other EGFR-targeting drugs. Clin Cancer Res 12:7242-7251.
19. + exchanger SLC9 gene family. Pflugers Arch 447:549-565.
20. + exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells. Breast Cancer Res 6:R616-R628.
21. + exchanger NHE1 in stress-induced signal transduction: Implications for cell proliferation and cell death. Pflugers Arch 452:249-259.
22. + exchanger, NH E1:structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 42:527-552.
23. + exchange, motility, and invasion induced by serum deprivation. J Biol Chem 275:5361-5369.
24. Reuter CWM, Morgan MA, Eckardt A. 2007. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96:408-416.
25. Scaltriti M, Baselga J. 2006 The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12:5268-5272.
26. Schoell WM, Janicek MF, Mirhashemi R. 1999. Epidemiology and biology of cervical cancer. Semin Surg Oncol 16:203-211.
27. Shen MR, Chou CY, Ellory JC. 2000. Volume-sensitive KCl cotransport associated with human cervical carcinogenesis. Pflugers Arch 440:751-760.
28. + exchanger isoform I during regulatory volume decrease of human cervical cancer cells. FEBS Lett 512:52-58.
29. Shen MR, Chou CY, Hsu KF, Ellory JC. 2002b. Osmotic shrinkage of human cervical cancer cells induces an extracellular Cl -dependent nonselective cation channel, which requires p38 MAPK. J Biol Chem 277:45776-45784.
30. Shen MR, Chou CY, Hsu KF, Hsu YM, Chiu WT, Tang MJ, Alper SL, Ellory JC. 2003. KCl cotransport is an important modulator of human cervical cancer growth and invasion. J Biol Chem 278:39941-39950.
31. Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ, Chou CY. 2006. Insulin-like growth factor I is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis 27:962-971.
32. + exchanger NHE1 in cell migration. Acta Physiologica 187:149-157.
33. + exchange. J Physiol 567:225-238.
34. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S. 1992. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 79:675-682.
35. Thomas RC. 1984. Experimental displacement of intracellular pH and the mechanism of its subsequent recovery. J Physiol 354:3P-22P.
36. Thomas JA, Buchsbaum RN, Zimniak A, Racker E. 1979. Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ. Biochemistry 18:2210-2218.
37. Vergote IB, Humblet Y, van Cutsem E, van Belle S, Kerger J, Van Laethem J, Canon J, Forget F, Strobbe E, van Oosterom A. 2005. A multicenter Phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data. J Clin Oncol (ASCO Annual Meeting Proceedings) 23:3162.
38. Yang W, Dyck JR, Wang H, Fliegel L. 1996. Regulation of NHE-1 promoter in mammalian myocardium. Am J Physiol 270:H259-H266.
39. zur Hausen H. 1991. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13.